What does the UK’s pro-innovation approach to AI mean for life sciences companies?

It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO: AI-inventions ‘not categorically unpatentable’

13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.

Biotechnology

The patentability of AI-related inventions

25 January 2024 Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.

More features

Killing the golden goose of US drug innovation (Part I): Follow the money

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

The flaw that landed Sanofi a win in the rare disease space

UK firm expands in Germany with more litigation hires

Sandoz blocked by UK court from seeking Xarelto profits

An update on patenting in Ukraine, Russia and Eurasia

The rise of pro-NPE and patent sentiment in the US

What does the UK’s pro-innovation approach to AI mean for life sciences companies?

More on this story

Editor's picks

Editor's picks

More features